


**Title:** The Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

**Authors:** G. Leclercq, H. Haegel, A. Schneider, A. Giusti, E. Marrer-Berger, C. Boetsch, A. Walz, V. Pulko, J. Sam, J. Challier, C. Ferlini, A. Odermatt, P. Umaña, M. Bacac, C. Klein

**Correspondance:** gabrielle.leclercq@roche.com



**In brief:** Dasatinib reversibly switches off T cell activation and proliferation, T cell cytotoxicity and cytokine release upon stimulation with T cell bispecific antibodies.